Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Outperform Rating at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. Wedbush’s price target indicates a potential upside of 95.31% from the stock’s previous close.

Several other analysts also recently commented on DMRA. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Guggenheim upped their price objective on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Finally, TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 1.3%

DMRA stock traded down $0.27 during mid-day trading on Tuesday, reaching $20.48. 142,063 shares of the company traded hands, compared to its average volume of 424,734. The firm’s 50 day moving average price is $28.18 and its 200 day moving average price is $26.27. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -6.08 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $3.50 and a fifty-two week high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jennifer Jarrett purchased 12,500 shares of the company’s stock in a transaction on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.40% of the stock is owned by insiders.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently made changes to their positions in DMRA. Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $42,146,000. Seven Fleet Capital Management LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $7,398,000. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $303,000. Finally, Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.